GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virax Biolabs Group Ltd (NAS:VRAX) » Definitions » Short Interest

Virax Biolabs Group (Virax Biolabs Group) Short Interest


View and export this data going back to 2022. Start your Free Trial

What is Virax Biolabs Group Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.


Competitive Comparison of Virax Biolabs Group's Short Interest

For the Biotechnology subindustry, Virax Biolabs Group's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Virax Biolabs Group's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Virax Biolabs Group's Short Interest distribution charts can be found below:

* The bar in red indicates where Virax Biolabs Group's Short Interest falls into.



Virax Biolabs Group (Virax Biolabs Group) Business Description

Traded in Other Exchanges
N/A
Address
20 North Audley Street, London, GBR, W1K 6LX
Virax Biolabs Group Ltd is a innovative biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against major global viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.